药品差别定价：成本效益分析能发挥作用吗？

Differential pricing of drugs: a role for cost-effectiveness analysis?

作者信息

Lopert Ruth, Lang Danielle L, Hill Suzanne R, Henry David A

机构信息

WHO Collaborating Centre for Training in Pharmacology and Rational Drug Use, School of Medical Practice and Population Health, Faculty of Health, University of Newcastle, New South Wales, Australia.

出版信息

Lancet. 2002 Jun 15;359(9323):2105-7. doi: 10.1016/S0140-6736(02)08911-0.

DOI:10.1016/S0140-6736(02)08911-0

PMID:12086780

Abstract

Internationally, the high costs of pharmaceutical products limit access to treatment. The principle of differential pricing is that drug prices should vary according to some measure of affordability. How differential prices should be determined is, however, unclear. Here we describe a method whereby differential prices for essential drugs could be derived in countries of variable national wealth, and, using angiotensin-converting enzyme inhibitors provide an example of how the process might work. Indicative prices for drugs can be derived by cost-effectiveness analysis that incorporates a measure of national wealth. Such prices could be used internationally as a basis of differential price negotiations.

摘要

在国际上，药品的高昂成本限制了治疗的可及性。差别定价原则是药品价格应根据某种可承受能力的衡量标准而有所不同。然而，差别价格应如何确定尚不清楚。在此，我们描述一种方法，通过该方法可以在国家财富各异的国家中得出基本药物的差别价格，并以血管紧张素转换酶抑制剂为例说明该过程可能如何运作。药品的指示性价格可通过纳入国家财富衡量指标的成本效益分析得出。此类价格可在国际上用作差别价格谈判的基础。